Breast Health and Risk Assessment
Benign findings versus true risk
Most breast lumps are benign. Fibroadenomas, simple cysts, and fibrocystic change do not meaningfully raise cancer risk. Proliferative lesions without atypia carry a small increase; atypical ductal or lobular hyperplasia and lobular carcinoma in situ (LCIS) carry a larger increase. LCIS is a marker of risk, not a precursor that requires clear margins.
Naming the risk factors
Age, female sex, family history on either side of the family, BRCA1/BRCA2 and other inherited mutations, chest radiation before age 30, early menarche, late menopause, nulliparity or late first birth, hormone therapy, obesity, alcohol, and physical inactivity all matter. Reproductive and hormonal exposures are best understood as cumulative estrogen exposure.
Quantifying risk
The Gail model estimates 5-year and lifetime risk of invasive breast cancer. It does not include BRCA status and should not be used for known carriers. Other models (BRCAPRO and similar) estimate the probability of a mutation. Common high-risk thresholds include a lifetime risk of about 20% or more by a validated model, prior LCIS or atypical hyperplasia, a known pathogenic mutation, and prior chest radiation. Dense breast tissue lowers mammographic sensitivity but is not the same as high risk.
Risk reduction
Options include tamoxifen or raloxifene, aromatase inhibitors in postmenopausal women, risk-reducing mastectomy, and salpingo-oophorectomy for BRCA carriers. These are shared decisions balancing benefit and toxicity.
Worked example. A 42-year-old whose mother and maternal aunt had breast cancer: calculate Gail risk and screen her for genetic-counseling criteria. If a BRCA mutation is found, Gail is the wrong tool; management follows carrier-specific guidance.